Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid)

靶向CD30嵌合抗原受体T细胞疗法（武汉波睿达生物）

Report date: 2023/05/05 17:09:09

Base Information

Drug NameAnti-CD30 CAR T-cell therapy (Wuhan Bio-Raid)
Drug Alias NameAnti-CD30 chimeric antigen receptor T-cell therapy -(Wuhan Bio Raid Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulators
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaHematologic NeoplasmsLymphoma, T-Cell, Peripheral +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan BioRaid Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan BioRaid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Large-Cell, AnaplasticHodgkin Disease
Inactive IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Extranodal NK-T-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A